secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001645113-25-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure Q3 revenue $167M (+8% YoY), net loss $37.3M; PMA for pancreatic cancer under review
--------------------------------------------------------------------------------

- Net revenues of $167.2M, up 8% YoY; US contributed $96.6M, Germany $20.3M, France $19.6M, Japan $9.4M.
- Net loss of $37.3M ($0.33 loss per share); adjusted EBITDA of $(3.0)M; gross margin 73% vs 77% YoY.
- 4,416 active patients globally as of Sept 30, 2025; Optune Gio prescriptions up 7% to 1,675.
- PMA for TTFields in locally advanced pancreatic cancer accepted by FDA; PMA for brain metastases from NSCLC planned Q4 2025.
- Cash and short-term investments $1,033.5M; Spain coverage for Optune Gio; Japan approval for Optune Lua with PD-1/L1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000043/0001645113-25-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000043/nvcr-20251030.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer